Hypotheses of neuroleptic action: Levels of progress

Wise, Roy A.

doi:10.1017/s0140525x00010621

Cited by 11 publications

(2 citation statements)

References 194 publications

(80 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is consistent with the effects of neurosurgical treatment, which may work by disrupting frontal and subcortical connections thought to be part of a dysfunctional neuroanatomical circuit in O C D (Model1 et al, 1989;Martuza et al, 1990). Neuroleptics may inhibit dopamine input to prefrontal and frontal regions (Wise, 1982) and thus might work synergistically with the SRIs in some patients. Curiously, treatment of O C D may be more successful in some patients after neurosurgery (Martuza et al, 1990;Greist, 1990).…”

mentioning

confidence: 99%

Efficacy of clomipramine in obsessive-compulsive disorder

Howland

2007

Anxiety

View full text Add to dashboard Cite

mentioning

confidence: 99%

Efficacy of clomipramine in obsessive-compulsive disorder

Howland

2007

Anxiety

View full text Add to dashboard Cite

“…They neglected to address a large body of literature on the action of antipsychotic medication in blocking dopamine receptors and decreasing mesolimbic and mesocortical dopamine function. Specifically, empirical evidence in the pharmacological literature indicates that the equivalence of therapeutic doses for humans of neuroleptics effectively shuts down in animals the mesocortical and mesolimbic dopamine input into prefrontal and premotor frontal cortical areas (Wise 1982). If therapeutic dosages of neuroleptics diminish dopamine function, would not this diminished dopamine function further decrease gain in context modules needed for adequate task performance by schizophrenia patients?…”

mentioning

confidence: 99%

Schizophrenic Deficits: Neuroleptics and the Prefrontal Cortex

Jobe

Harrow

Martin

et al. 1994

Schizophrenia Bulletin

View full text Add to dashboard Cite

Modern techniques have been applied to brain modeling, based on recent approaches in the artificial intelligence field that use brain-like "connectionistic" computational architectures. The model proposed by Cohen and Servan-Schreiber uses a gain parameter which they identify with dopamine function. They apply their model to neuroleptically treated schizophrenia patients who show improved task performance which they link to increased dopamine function and increased gain in the prefrontal cortex. However, evidence indicates that antipsychotic medications block dopamine (especially D2) receptors, decreasing mesolimbic and mesocortical dopamine function. If therapeutic dosages of neuroleptics diminish dopamine function, this would decrease gain in context modules needed for adequate task performance. Schizophrenia patients would perform more poorly by further reducing gain in their already compromised context modules. The current investigators suggest three possible ways to resolve this difficulty, to explain why normals perform more poorly when taking neuroleptics, although acute schizophrenia patients' performance may be enhanced in several areas. Evidence would suggest that multiple processes occur simultaneously in neuroleptically treated patients with some processes counterbalancing others.

show abstract

Tests Involving Pressing for Intracranial Stimulation as an Early Procedure for Screening Likelihood of Addiction of Opioids and Other Drugs

Reid

1987

Methods of Assessing the Reinforcing Properties of Abused Drugs

View full text Add to dashboard Cite

Hypotheses of neuroleptic action: Levels of progress

Cited by 11 publications

References 194 publications

Efficacy of clomipramine in obsessive-compulsive disorder

Efficacy of clomipramine in obsessive-compulsive disorder

Schizophrenic Deficits: Neuroleptics and the Prefrontal Cortex

Tests Involving Pressing for Intracranial Stimulation as an Early Procedure for Screening Likelihood of Addiction of Opioids and Other Drugs

Contact Info

Product

Resources

About